Developer docs
API playgroundTry for free, no card

Search company profiles

Scientia Clinical Research

Full company profile

uuid000jfow

Namestring
Scientia Clinical Research
Legal namestring
Scientia Clinical Research
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Scientia Clinical Research is an Australian medical center founded in 2016 that conducts healthy volunteer and oncology clinical trials, operating from Randwick with 11-50 employees as a private Phase I trial site.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRandwick, Australia
HQ citystring
Randwick
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
clinical trial services, oncology research, healthy volunteer trials, medical research center, clinical studies
Industry1 code
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Clinical Research Services
Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Scientia Clinical Research operates a medical center in Randwick, Australia that conducts healthy volunteer clinical trials and oncology clinical trial services. The organization functions as a clinical research site supporting sponsor-led drug and treatment development studies, with a focus on first-in-human healthy volunteer studies and oncology patient trials.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Healthy Volunteer Clinical Trials
CategoryClinical Research Services
2Oncology Clinical Trial Services
CategoryClinical Research Services
No data
Peers10 records
TypeDirect peer
Description

CMAX is an Adelaide-based early-phase clinical trial facility specializing in healthy volunteer Phase 1 studies. It is the closest Australian direct peer to Scientia's healthy volunteer offering, running similar first-in-human pharmacology trials for biotech sponsors.

TypeDirect peer
Description

Nucleus Network operates dedicated Phase 1 clinical trial units in Melbourne and Brisbane focused on healthy volunteer and patient studies (including oncology). It is a direct Australian competitor with similar scope to Scientia's combined healthy volunteer plus oncology offering.

TypeDirect peer
Description

Linear Clinical Research is a Perth-based early-phase oncology and healthy volunteer trial unit affiliated with the Harry Perkins Institute. Its combination of first-in-human oncology and Phase 1 healthy volunteer services makes it highly comparable to Scientia's stated dual focus.

TypeDirect peer
Description

Q-Pharm is a Brisbane-based early-phase clinical trial unit conducting Phase 1 healthy volunteer and patient studies. It is a direct Australian Phase 1 peer competing for the same biotech sponsor placements.

TypeBroad incumbent
Description

Novotech is a large Australia-headquartered CRO with deep early-phase and oncology trial expertise across the Asia-Pacific region. While far larger in scale, it competes with Scientia for biotech-sponsored Phase 1 oncology work and provides context on Australia's regional CRO ecosystem.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with extensive Phase 1 and oncology clinical operations globally, including dedicated early-phase units. It represents the upper-end incumbent alternative that biotech sponsors may select over independent sites like Scientia.

TypeBroad incumbent
Description

ICON plc is a leading global CRO with strong early-phase and oncology capabilities following its PRA Health Sciences merger. It competes broadly with Scientia for sponsor-mandated Phase 1 oncology study placements through its clinical trial site network.

TypeBroad incumbent
Description

Parexel is a global clinical and bioanalytical services provider with deep early-phase and oncology expertise. It is included as a broad incumbent peer representing the full-service CRO alternative to boutique Phase 1 sites like Scientia.

TypeBroad incumbent
Description

Charles River operates an early-discovery and clinical services business including Phase 1 units and bioanalytical capabilities. As a broad incumbent in the early-phase CRO market it competes with independent Phase 1 sites like Scientia for biotech sponsor allocations.

10Scientia Clinical Research Sydney (academic/adjacent)
TypeOthers
Description

The Randwick precinct (which includes Prince of Wales Hospital, UNSW-affiliated research activity, and the Bright Alliance/UNSW clinical research facilities) is itself an adjacent research ecosystem. Academic Phase 1 groups and university-affiliated clinical trial units in this precinct are adjacent peers, sharing the same Sydney oncology patient catchment and competing for similar investigator-initiated and industry-sponsored early-phase studies.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scientia Clinical Research

Clinical Research Servicesscientiaclinicalresearch.com.au

Scientia Clinical Research is an Australian medical center founded in 2016 that conducts healthy volunteer and oncology clinical trials, operating from Randwick with 11-50 employees as a private Phase I trial site.

Scientia Clinical Research firmographics

Firmographics
Name
Scientia Clinical Research
Legal name
Scientia Clinical Research
Website
https://scientiaclinicalresearch.com.au
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Scientia Clinical Research is an Australian medical center founded in 2016 that conducts healthy volunteer and oncology clinical trials, operating from Randwick with 11-50 employees as a private Phase I trial site.
Ownership category
akta.pro rank

Scientia Clinical Research industry classification

Industry
Product category
Clinical Research Services
NAICS
Medical Laboratories (621511)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial services
  • Oncology research
  • Healthy volunteer trials
  • Medical research center
  • Clinical studies

Where Scientia Clinical Research is headquartered

Location

Headquarters

HQ city
Randwick
HQ country
Australia
HQ region
Oceania

Markets served

Scientia Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Scientia Clinical Research product offering

Product offering

Core offering

Scientia Clinical Research operates a medical center in Randwick, Australia that conducts healthy volunteer clinical trials and oncology clinical trial services. The organization functions as a clinical research site supporting sponsor-led drug and treatment development studies, with a focus on first-in-human healthy volunteer studies and oncology patient trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthy Volunteer Clinical Trials
  • Oncology Clinical Trial Services

Companies that use Scientia Clinical Research

Customer profile

Ideal customer profiles1 record

Scientia Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Scientia Clinical Research competitors and assessment

Company assessment

Direct peers

  • CMAX Clinical Research: CMAX is an Adelaide-based early-phase clinical trial facility specializing in healthy volunteer Phase 1 studies. It is the closest Australian direct peer to Scientia's healthy volunteer offering, running similar first-in-human pharmacology trials for biotech sponsors.
  • Nucleus Network: Nucleus Network operates dedicated Phase 1 clinical trial units in Melbourne and Brisbane focused on healthy volunteer and patient studies (including oncology). It is a direct Australian competitor with similar scope to Scientia's combined healthy volunteer plus oncology offering.
  • Linear Clinical Research: Linear Clinical Research is a Perth-based early-phase oncology and healthy volunteer trial unit affiliated with the Harry Perkins Institute. Its combination of first-in-human oncology and Phase 1 healthy volunteer services makes it highly comparable to Scientia's stated dual focus.
  • Q-Pharm: Q-Pharm is a Brisbane-based early-phase clinical trial unit conducting Phase 1 healthy volunteer and patient studies. It is a direct Australian Phase 1 peer competing for the same biotech sponsor placements.

Broad incumbents

  • Novotech: Novotech is a large Australia-headquartered CRO with deep early-phase and oncology trial expertise across the Asia-Pacific region. While far larger in scale, it competes with Scientia for biotech-sponsored Phase 1 oncology work and provides context on Australia's regional CRO ecosystem.
  • IQVIA: IQVIA is the world's largest CRO with extensive Phase 1 and oncology clinical operations globally, including dedicated early-phase units. It represents the upper-end incumbent alternative that biotech sponsors may select over independent sites like Scientia.
  • ICON plc: ICON plc is a leading global CRO with strong early-phase and oncology capabilities following its PRA Health Sciences merger. It competes broadly with Scientia for sponsor-mandated Phase 1 oncology study placements through its clinical trial site network.
  • Parexel International: Parexel is a global clinical and bioanalytical services provider with deep early-phase and oncology expertise. It is included as a broad incumbent peer representing the full-service CRO alternative to boutique Phase 1 sites like Scientia.
  • Charles River Laboratories: Charles River operates an early-discovery and clinical services business including Phase 1 units and bioanalytical capabilities. As a broad incumbent in the early-phase CRO market it competes with independent Phase 1 sites like Scientia for biotech sponsor allocations.

Others

  • Scientia Clinical Research Sydney (academic/adjacent): The Randwick precinct (which includes Prince of Wales Hospital, UNSW-affiliated research activity, and the Bright Alliance/UNSW clinical research facilities) is itself an adjacent research ecosystem. Academic Phase 1 groups and university-affiliated clinical trial units in this precinct are adjacent peers, sharing the same Sydney oncology patient catchment and competing for similar investigator-initiated and industry-sponsored early-phase studies.

Market position

Customer concentration

Scientia Clinical Research social profiles

Digital presence

Scientia Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scientia Clinical Research leadership team

Management profile

Number of profiles

Scientia Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scientia Clinical Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scientia Clinical Research

What does Scientia Clinical Research do?

Scientia Clinical Research operates a medical center in Randwick, Australia that conducts healthy volunteer clinical trials and oncology clinical trial services. The organization functions as a clinical research site supporting sponsor-led drug and treatment development studies, with a focus on first-in-human healthy volunteer studies and oncology patient trials.

Is Scientia Clinical Research a public or private company?

Scientia Clinical Research is a private company. It is classified as unknown and is currently operating.

When was Scientia Clinical Research founded?

Scientia Clinical Research was founded in 2015. It employs 101 to 250 people.

Where is Scientia Clinical Research based?

Scientia Clinical Research is headquartered in Randwick, Australia, in the Oceania region.

Who are Scientia Clinical Research's main competitors?

Direct peers on record are CMAX Clinical Research, Nucleus Network, Linear Clinical Research and Q-Pharm. Broad incumbents are Novotech, IQVIA, ICON plc, Parexel International and Charles River Laboratories. Scientia Clinical Research Sydney (academic/adjacent) is listed as an others.

Does Scientia Clinical Research have an API?

No public API is recorded for Scientia Clinical Research.

What industry is Scientia Clinical Research in?

Scientia Clinical Research's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 621511 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireRecce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical ResearchRecce Pharmaceuticals completed first cohort dosing of R327 in a Phase I/II UTI trial at Scientia Clinical Research, with both male and female subjects receiving 2,500mg IV at faster infusion rates. The drug was safe and well-tolerated, and an independent safety committee is expected to recommend continuing the study.GlobeNewswireRecce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical ResearchRecce Pharmaceuticals dosed male and female subjects in a Phase I/II UTI trial of RECCE 327 at faster infusion rates at Scientia Clinical Research. The study is tracking to meet primary endpoints, with remaining subjects to be dosed this week and expected data read-outs in H2 2023.GlobeNewswireClaritas Provides Update Regarding Phase 1 Clinical StudyClaritas Pharmaceuticals terminated its agreement with CMAX and moved its Phase 1 study of R-107 to Scientia Clinical Research in Sydney, Australia. The company expects to complete the study by Q1 2022, after which it plans a Phase 2a study for pulmonary arterial hypertension and U.S. grant funding for COVID-related lung disease.GlobeNewswireOmniComm Systems Announces First Australia ClientOmniComm Systems announced that Scientia Clinical Research, a Sydney-based early-phase clinical trial facility, selected its TrialOne clinic automation and eSource application. This marks OmniComm's first customer in Australia and New Zealand, supporting its regional expansion in the clinical trials market.